| Previous Close | 36.70 |
| Open | 36.76 |
| Bid | 36.74 x 3100 |
| Ask | 36.72 x 900 |
| Day's Range | 36.62 - 37.00 |
| 52 Week Range | 26.45 - 43.08 |
| Volume | 33,369,696 |
| Avg. Volume | 46,452,996 |
| Market Cap | 204.16B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 23.88 |
| EPS (TTM) | 1.54 |
| Earnings Date | Feb. 02, 2021 |
| Forward Dividend & Yield | 1.56 (4.25%) |
| Ex-Dividend Date | Jan. 28, 2021 |
| 1y Target Est | 41.79 |
- Editor's PickYahoo Finance Video
Doctor: 'Vaccine rollout is so far behind where we need it to be'
Emergency Medicine Physician Dr. Steven McDonald joins Yahoo Finance's Kristin Myers to break down the latest coronavirus developments, as U.S. hospitalizations begin to decline.
- Editor's PickYahoo Finance
Coronavirus update: US surpasses 400,000 COVID-19-related deaths
U.S. hits 400,000 deaths as virus spread continues to overwhelm parts of the country. Meanwhile, vaccine chaos hampers efforts.
ReutersPeru says Sinopharm, Pfizer seek approval for their COVID-19 vaccines
China's Sinopharm Group and Pfizer Inc have requested approval for use of their COVID-19 vaccines in Peru as the Andean country grapples with a second wave of the coronavirus, a health official said on Tuesday. Carmen Ponce, general director of state drug regulator Digemid, said both drugmakers requested the registration last week after presenting "preliminary information" from their Phase III COVID-19 vaccine trials. Ponce added that authorization requests from other vaccine makers, such as AstraZeneca Plc and Russia's Gamaleya, are expected in the next few days.
